PTO/SB/08A (08-00)
Approver use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

heet	ı	of	

Com	plete if Known-	
Application Number	10/075,073	
Filing Date	February 13, 2002	
First Named Inventor	William Glen Harter, et al	
Group Art Unit	-1645 162U	_
Examiner Name	Unknown	
Attorney Docket Number	A0000428-01-CFP	

			U.S. PATENT DOCU	MENTS	
xaminer nitials"	Cite No.1	U.S. Patent Document  Number Kind Code <sup>2</sup> (If known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Solumns, Lines, When Relevant Passages or Relevant Figures Repose
mT		5,948,780	Peterson, Jr., et al	09/07/1999	514/253
77	1	6,008,243	Bender, et al	12/28/1999	514/422
	:/	5,403,843	Akimoto, et al	04/04/1995	514/258 2 4
$\dashv$		5,284,661	Morimoto, et al	02/08/1994	424/464 C
$\neg \neg$	1/	5,817,819	Furuya, et al	10/06/1998	346/114 92
	1/	5,521,181	Meyer, et al	05/28/1996	514/249 7 0
	/	6,166,019	Meyer, et al	12/26/2000	514/252.10 20 2
$\neg \neg$	-/	5,334,596	Hartman, et al	08/02/1994	514/301 <b>3</b> 3 514/258 <b>3</b>
	17	4,835,157	Press, et al	05/30/1989	514 /258 2
W	V	5,792,767	Meyer, et al	08/11/1998	514/249
	Ť				8

			<u></u>	FOR	EIGN PATENT DOCUMENT	S		
Examiner	Cite		Foreign Patent Docum	nent Kind Code <sup>5</sup>	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant	
initials*	No.1	Office <sup>3</sup>	Number <sup>4</sup>	(if known)	Applicant of Cited Document	MM-DD-YYYY	Passages or Relevant Figures Appear	, T6
TNI	1/	∤wo	01/63244 A1		Chen, et al	08/30/2001		
1	<i>i/</i>	wo	97/07119		Furuya, et al	02/27/1997		
	1	wo	98/54116		Castelhano, et al	12/03/1998		
	7	wa	96/22991		Meyer, et al	08/01/1996		
	1/	wo	95/28405		Furuya, et al	10/26/1995		$\downarrow$
	V	wa	92/20687		Chakravarty, et al	11/26/1992		
$\Box$	1	wo	00/61583		Klein, et al	10/19/2000		$oldsymbol{\perp}$
	V	wo	00/04027		Meyer, et al	01/27/2000		
TNI		wo	98/49899		Atherall, et al	11/12/1998		
-		FP	0 530 537 B1		Akimoto, et al	01/08/1997		

			·	
Examiner	7.0	Date	1 1/27	2/01/
Signature	11/2000	Considered	6/6	709

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00)

Approvement of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of Sheet 2 6

- C m	pl t if Known
Application Number	10/075,073
Filing Date	February 13, 2002
First Named Inventor	William Glen Harter, et al
Group Art Unit	-1643 1624
Examiner Name	Unknown
Attorney Docket Number	A0000428-01-CFP

				U.S. PATENT DOCU	MENTS	
Examiner Initials*	Cite No.1	U.S. Pater Number	t Document  Kind Code <sup>2</sup> (If known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
						SENTER 1
		<del></del>			<del> </del>	
<del></del>			<del>-  -  </del>			<u></u>
				·		5001250
						200
						8
		. <u>.</u>			_	
			<del>  </del>			
			<del></del>			

				FORE	GN PATENT DOCUMENT	5		
	Foreign Patent Document		ent	Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant	Г	
Examiner Initials	Cite No.1	Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (If known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	Ţ6
TNT	1	EP	0 443 568 A1		Morimoto, et al	08/28/1991		
- ) 1	V	EP	0 443 568 B1		Morimoto, et al	06/12/1996		
_	1	EP	0 492 316 A1		Akimoto, et al	07/01/1992		
	7	EP	0 502 725 A2		de Laszlo	09/09/1992		
	V	EP	0 530 537 A1		Akimoto, et al	03/10/1993		
	1/.	EP	0 416 740 A2		Smith, et al	03/13/1991		
	1/	EP	0 297 661 B1		Janssens, et al	09/16/1992		
1	5//	EP	0 438 261 A2		Akimoto, et al	07/24/1991		
7	77	EP	0 297 661 A1		Janssens, et al	01/04/1989		
71/1	1	EP	0 282 133 B1		Janssens, et al	07/28/1993	•	

Examiner	110	Date	1 9204
Signature	Mon	Considered	6-220-1

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Petent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00)
Approver or use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete If Kn wn --

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

		<u> </u>	
Sheet	3	of	6

	plete if Kn wn
Application Number	10/075,073
Filing Date	February 13, 2002
First Named Inventor	William Glen Harter, et al
Group Art Unit	1645 1624
Examiner Name	Unknown
Attorney Docket Number	A0000428-01-CFP

				U.S. PATENT DOCU	IMENTS		
Examiner Initials*	Cite No.1	U.S. Paten Number	Kind Code <sup>2</sup>	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TOY OF THE STATE O
	•						田
						<u></u>	<b>孟</b>
							<u> </u>
							==1
							2
			$\longrightarrow \longmapsto$				0/29
							- 8
					<del></del>		<u>U</u>
					<del>- </del>		
			-+		+ +-		
		····			<u> </u>		
	-				<del></del>		
			<del>-    </del>			<del></del>	
				<del></del>	<del>                                     </del>		
-							<u> </u>
$\overline{}$							

				FORE	IGN PATENT DOCUMENTS	S		
Examiner	Cite		Foreign Patent Docum	ent Kind Code <sup>5</sup>	Name of Patentee of	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant	
Initials*	No.1	Office <sup>3</sup>	Number <sup>4</sup>	(If known)	Applicant of Cited Document	MM-DD-YYYY	Passages or Relevant Figures Appear	Te
M		EP	0 282 133 A2		Janssens, et al	09/14/1988		
·INI		JР	5-213956	<b>*</b>	Japanese Language	8/24/1993		
W		wo	96/24597		Furuya, et al	08/15/1996		
, , ,								╀
						ļ	·	┼
		$\vdash$	·		·	<u> </u>		4
		$\vdash$			<del> </del>	<del>                                     </del>		╁
<b> </b>					<del></del>	<del> </del>		+
						<del> </del>		+-
	L	11				<u> </u>		

Examiner	110~~	Date	102-011
Signature	11/000	Considered	6-2009

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistent Commissioner for Patents, Washington, DC 20231.

Counder struckeres in JP 5-213956 only

+

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>8</sup> Applicant is to place a check mark here if English language Translation is attached.

Sheet

PTO/SB/08B (08-00)
Approved or use through 10/31/2002. OMB 0651-0031
U. S. Patent and Tradernark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of

(use as many sheets as necessary)

C mpl te if Known 10/075,073 **Application Number** February 13, 2002 **Filing Date** William Glen Harter, et al First Named Inventor -1645 16 2e **Group Art Unit** Unknown Examiner Name Attorney Docket Number A0000428-01-CFP

			<u> الد</u>	
		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	$\mathcal{Q}$	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	NICH	tτ²
TNI		MONTANA, John, et al, "The design of selective non-substrate-based matrix metalloproteinase inhibitors" Current Opinion in Drug Discovery & Development, 2000; 3(4), pp 353-361,	JOUGE	10005
		CLARK, Ian, et al, "Matrix metalloproteinase inhibitors in the treatment of arthritis", Current Opinions in Anti-inflammatory & Immunomodulatory Investigational Drugs, 2000; 2(1), pp 16-25	600	3
	1	CHEN, James, et al, "Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design", J. Am. Chem. Soc., 2000, 122; pp 9648-9654		
	1	HIROTA, Kosaku, et al, "Synthesis of 6-Substituted Thieno[2,3-d]pyrimidine-2,4(1H,3H)-diones", J. Heterocycl. Chem., 1990; 27(3); pp 717-721		
	V	RAJAPPA, S., et al, "Synthesis of Thiophenes: Part III* - Further Variations in the Substitution Pattern", Indian J. Chem., Vol. 12, 1974; pp 1-3		
	/	HCAPLUS Abstract 1998: 542760; "Preparation of bicyclic-substituted hexahydrobenz [e] isoindoles as a adrenergic antagonists" > 1998.		
	1	HCAPLUS Abstract 1990: 514925; "Pyrimidines. 65. Synthesis of 6-substituted thieno [2,3-d] pyrimidine-4(1H,3H) - diones" 1990	2	
	V	HCAPLUS Abstract 1974: 463420: "Synthesis of thiophenes. III. Further variations in the substitution pattern" 1974.		
	V	Derwent Abstract 2000-687031/67, "New xanthine derivatives are inhibitors of cellular processes mediated by interleukin-12 for treating inflammatory responses e.g. chronic inflammatory disease, chronic intestinal inflammation, arthritis, psoriasis and asthma (Eng)", 2000,	i	
		Derwent Abstract 92-415690/50, "New Pyrimidinone derivs. are angiotensin II antagonists - for treating hypertension, congestive heart failure, renal failure, Alzheimer's disease, amnesia schizophrenia etc (Eng)"	g	
	V	1992 -		
<u>, , , , , , , , , , , , , , , , , , , </u>		Derwent Abstract 92-302020/37, "New fused pyrimidone derivs are angiotensin II antagonists to treat hypertension, congestive heart failure, Alzheimer's disease, amnesia, anxiety, schizophrenia, etc. (Eng)"	,	

—			1 1
Examiner	112-1	Date	6/27/04
Signature	10082	Considered	01220

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

•	
lease type a plus sign (+) inside this bo	+

PTC/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

ider the Paperwork Reduction Act of 1995, no persons are required to re	spond to a collection of information un	
Substitute for form 1449B/PTO	Con	plt ifKn wn
	Application Number	10/075,073
INFORMATION DISCLOSURE	Filing Date	February 13, 2002
STATEMENT BY APPLICANT	First Named Inventor	William Glen Harter, et al
STATEMENT BY AFFEIGANT	Group Art Unit	1645
	<u> </u>	Unknown

(use as many sheets as necessary)

Sheet 5 of 6

 Group Art Unit
 1645

 Examiner Name
 Unknown

 Attorney Docket Number
 A0000428-01-CFP

İ				7
Ĭ			OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	킾
	Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	D ¥ CO
	TMI	/	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  Derwent Abstract 91-254180/35, "New angiotensin-II antagonising fused thiophene derivatives - used for treating hypertension and circulatory diseases including heart diseases and stroke", 1991.	) Janaa
		V	Derwent Abstract 89-192246/26, "New 3-piperidinyl:alkyl-thieno: or furo pyrimidine-2.4-di:one cpds useful as seratonin antagonists and alpha adrenergic blockers" / 989.	
		,	Derwent Abstract 2000-195023/17, "New ipiperazinyl pyrimidine dione derivatives used as selective alpha-ID adrenoceptor antagonists for treating benign prostatic hyperplasia, hypertension, detrusor instability and incontinence (Eng)" , 2000	
		v	Derwent Abstract 2001-158207/16, "New piperazinyl pyrimidine dione derivatives are selective alpha-1D adrenoceptor antagonists used for treatment of e.g. hypertension"	
			Derwent Abstract 96-362624/36, "New bi:cyclic substd. hexa:hydro-benz-isoindole derivs are alpha-1 adrenergic antagonists, used in treatment of benign prostatic hyperplasia (Eng)", 1996.	
		V	Derwent Abstract 89-008928/02, "New bi:cyclic heterocycle substd. hexa-hydro-1H-azepine - and pyrrolidine cpds., have anti-histaminic properties, for treatment of e.g. allergic rhinitis, allergic asthma, etc." 1989.	
1		·/	Derwent Abstract 88-258874/37, "New 1-alkyl substd. benzimidazole derivs having anti-histaminic activity and used for treating allergic diseases such as allergic asthma", 1988,	
		V	Derwent Abstract 91-216939/30, "New condensed heterocyclic glutemic acid derivs., - active against enzyme using folic acid and antitumour agents for treating e.g. leukemia", 1991.	
•		U.	Derwent Abstract 99-080786/07, "New thiophene- and pyrrole-based hetero-aromatic compounds - are (ant)agonists of cell surface receptors, useful e.g. for inhibiting unwanted cell growth e.g. due to cancer (Eng.)", 1999.	
		V	Derwent Abstract 97-165234/15, "New thieno-pyrimidine derivs. are endothelin antagonists useful for treating e.g. acute renal failure, cardiac infarction, liver insufficiency, organ hypo-function and vasoconstriction (Eng)", 1997.	
	TW	V	Derwent Abstract 96-384384/38, "New 2,4(1H, 3H)-di:oxo-5-(aminoalkyl)thieno(2,3-d)-pyrimidine derivs are gonadotropin-releasing hormone antagonistic agents useful in prevention and treatment of sex hormone dependent diseases (Eng)", 19962	

Examiner	110	Date	1	22/04
Signature	100m	Considered	6/	2 - 1 - 1

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

<u> </u>		C m	pl t if:Kn wn				
	ute for form 1449B/PTO	Application Number	10/075,073				
INFO	ORMATION DISCLOSURE	Filing Date	February 13, 2002				
STA	ATEMENT BY APPLICANT	First Named Inventor	William Glen Harter,				
		Group Art Unit	1645				
L	(use as many sheets as necessary)	Examiner Name	Unknown				
Sheet	6 of 6	Attorney Docket Number	A0000428-01-CFP				
	OTHER PRIOR ART - N	ON PATENT LITERATURE DO	CUMENTS				
Examiner	Cite Include name of the author (in CAPITA item (book, magazine, journal, serial, sy	AL LETTERS), title of the article (when	appropriate), title of the				
I hitials	total (sook, magazine, journal, series, sy	city and/or country where published.	**************************************				
	Derwent Abstract 95-382760/49, "Fused by	bicyclics as gonadotropin releasi	ng hormone antagonists - use				
M	treating hormone related cancers, benign	prostatic hypertrophy, acne vulga	aris, etc. (Eng)" , 1995,				
1 ( )			· · · · · · · · · · · · · · · · · · ·				
	Derwent Abstract 93-299636/38, "New co						
	soluble antitumour agent and have good s	torage stability in cells", 19	93.				
	D	Air	derive for treating				
	Derwent Abstract 93-078155/10, "New and chorlocarcinoma, leukaemia, breast adeno	actumour condensed pyritudine acarcinoma, squamous cell carcin	oma, lung cancer, lympho				
	sarcoma, etc. and also rheumatism (Eng)"	; 1993.					
	Derwent Abstract 92-218561/27, "Antitum	noural condensed heterocyclic of	igo:glutamate derivs for tre				
	leukaemia, squamous cell carcinoma, lym	phatic sarcoma, small cell cance	r of the lung etc. (Eng)", 19				
	\[ \begin{align*} \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	leukaemia, squamous cell carcinoma, lymphatic sarcoma, small cell cancer of the lung etc. (Eng)", 19					
	Derwent Abstract 96-267825/27, "New he	exa:hydro benz(e)isoindole cpds.	- are useful in treatment of b				
	prostatic hyperplasia (Eng)" 1996	<del>2</del> *					
<del>                                     </del>	D 404 040400/00 HE	d (bi (2.2 a)ninosidono o	arbovamida acide are fibria				
	Derwent Abstract 94-248420/30, "Furano- receptor antagonists, inhibit blood platelet	- and unieno- (5,2-c)piperidone c	d emboli treatment:				
	t / receptor amagomsis, namon blood practice	aggiogation, asoc in anomor an					
	Derwent Abstract 91-075241/11, "Heteroc	cyclic peptide derivs, useful as re	nin inhibitors - in the treatme				
	hypertension, congestive heart failure, retr	o-viral diseases and central nerv	ous system disorders" 19				
	HCAPLUS Abstract 1996:580284: "Prepa	aration of heterocyclyl-substitute	d benz[3]isoindoles as x1				
OK	adrenergic antagonists", 1996.						
1/01	/ : / / 5 /						
	<del>                                     </del>						
	1 1						

Date

Considered

Examiner

Signature

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.